Experimental validation of a commercial 3D dose verification system for intensity-modulated arc therapies.

We validate the dosimetric performance of COMPASS®, a novel 3D quality assurance system for verification of volumetric-modulated arc therapy (VMAT) treatment plans that can correlate the delivered dose to the patient's anatomy, taking into account the tissue inhomogeneity. The accuracy of treatment delivery was assessed by the COMPASS® for 12 VMAT plans, and the resulting assessments were evaluated using an ionization chamber and film measurements. Dose-volume relationships were evaluated by the COMPASS® for three additional treatment plans and these were used to verify the accuracy of treatment planning dose calculations. The results matched well between COMPASS® and measurements for the ionization chamber (≤3%) and film (73-99% for gamma((3%/3 mm)) < 1 and 98-100% for gamma((5%/5 mm)) < 1) for the phantom plans. Differences in dose-volume statistics for the average dose to the PTV were within 2.5% for three treatment plans. For the structures located in the low-dose region, a maximum difference of <9% was observed. In its current implementation, the system could measure the delivered dose with sufficient accuracy and could project the 3D dose distribution directly on the patient's anatomy. Slight deviations were found for large open fields. These could be minimized by improving the COMPASS® in-built beam model.